<DOC>
	<DOCNO>NCT02026154</DOCNO>
	<brief_summary>The study objective clarify ground heart exertional dyspnoea stenocardia patient well-controlled stage I II hypertension accord European Society Hypertension , without change epicardial coronary artery CT coronary angiography normal rest echocardiography result , assess potential early marker heart hypertrophy failure patient hypertension .</brief_summary>
	<brief_title>Finding Early Predictors Myocardial Dysfunction</brief_title>
	<detailed_description>The study allow identification patient hypertension , early introduction pharmacological treatment heart failure HF consider . Evaluation detection asymptomatic myocardial dysfunction include potential heart failure marker : cardiotrophin 1 , cystatin C , serum syndecan-4 , collagen III N-terminal propeptide [ PIIINP ] , NT-proBNP , IL1RL1 modern echocardiography method order increase effectiveness prevention , diagnosis treatment optimalization . Material study plan 100 person ( age 30-70 year old ) include study , patient stage I II primary hypertension accord European Society Hypertension : Group A- 15 patient without symptom heart failure Group B- 30 patient exertional dyspnoea Group C - 40 patient overt heart failure In group B ( patient exertional dyspnea/stenocardia ) include patient undergone CT coronary angiography without identify change epicardial coronary artery , facilitate answer present purpose research . Patients group A B normal rest echocardiography treat maximum 2 antihypertensive drug ( ACE inhibitor sartan therapy base ) , accord follow regimen : ACEI/ARB + diuretic ACEI/ARB + calcium channel antagonist Group C - treatment accordance standard heart failure . Each patient inform objective study give write consent participate . After sign informed consent patient perform follow test : - Interview documentation analysis , - Physical examination , - Electrocardiogram - Echocardiography rest submaximal exercise bicycle ergometer - Levels marker : cystatin C , cardiotrophin-1 , Procollagen III N-Terminal Propeptide ( PIIINP ) , Syndecan 4 ( SDC4 ) NT-proBNP , IL1RL1 . Each patient inform objective study give write consent participate .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>person ( age 3070 year old ) include study , patient stage I II primary hypertension accord European Society Hypertension coronary artery disease history coronary artery disease ( A , B ) unstable hypertension positive stress test NYHA class IIIIV heart failure percutaneous surgical revascularization diabetes GFR &lt; 60 hyperthyroidism hypothyroidism active smoker implant pacemaker obesity level II III ECGarrhythmia pregnant lactating congenital heart disease hemodynamically significant acquire heart defect cardiomyopathy ( A , B ) cancer anemia abuse alcohol drug chronic inflammatory disease give informed consent participate study</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>hypertension , biomarkers , echocardiography , heart failure</keyword>
</DOC>